Pneumoconiosis Market Report 2026

Pneumoconiosis Market Overview

• Pneumoconiosis market size has reached to $5.59 billion in 2025 • Expected to grow to $8.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: The Influence Of Smoking Prevalence On The Growth Of Market Due To Increasing Incidence Of Smoking-Related Lung Diseases • Market Trend: Adoption Of AI Based Portable Diagnostic Devices To Enhance Pneumoconiosis Screening • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pneumoconiosis Market?

Pneumoconiosis is a group of lung diseases caused by inhaling certain types of dust, usually over a long period, which leads to inflammation and scarring of lung tissue. This damage can impair the lungs' ability to exchange oxygen effectively, resulting in symptoms such as shortness of breath, coughing, and decreased exercise tolerance. The main types of pneumoconiosis are asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, others. Asbestosis is a chronic lung condition caused by inhaling asbestos fibers over a long period. The various treatment include medication, oxygen therapy, pulmonary rehabilitation, others. The various route of administration includes oral, inhalational, others with various diagnostic methods such as chest x-ray, computed tomography scan, lung function tests, bronchoscopy. These are used by various end users such as hospitals, specialty clinics, diagnostic centers, others.

What Is The Pneumoconiosis Market Growth Forecast?

The pneumoconiosis market size is expected to see strong growth in the next few years. It will grow to $8.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing implementation of preventive screening programs, rising investments in advanced pulmonary diagnostics, growing focus on occupational safety compliance, expansion of personalized respiratory care approaches, increasing research into fibrosis management therapies. Major trends in the forecast period include increasing adoption of advanced diagnostic imaging techniques, rising focus on early disease detection programs, growing use of long-term oxygen therapy solutions, expansion of occupational health monitoring initiatives, enhanced emphasis on pulmonary rehabilitation services.

Global Pneumoconiosis Market Segmentation

1) By Type: Asbestosis, Berylliosis, Byssinosis, Coal Workers Pneumoconiosis, Silicosis, Other Types 2) By Treatment: Medication, Oxygen Therapy, Pulmonary Rehabilitation, Other Treatments 3) By Route Of Administration: Oral, Inhalational, Other Route Of Administrations 4) By Diagnostic Method: Chest X-ray, Computed Tomography Scan, Lungfunction Tests, Bronchoscopy 5) By End Users: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-users Subsegments: 1) By Asbestosis: Pleural plaques, Diffuse pleural thickening, Rounded atelectasis, Lung cancer (as asbestos-related), Mesothelioma 2) By Berylliosis: Acute beryllium disease, Chronic beryllium disease (CBD), Hypersensitivity pneumonitis-like response 3) By Byssinosis: Acute byssinosis (early-stage), Chronic byssinosis, Work-related asthma 4) By Coal Workers’ Pneumoconiosis (CWP): Simple CWP, Complicated CWP (Progressive Massive Fibrosis - PMF), Caplan’s syndrome 5) By Silicosis: Acute silicosis, Accelerated silicosis, Chronic silicosis, Silicotuberculosis 6) By Other Types: Talcosis, Siderosis, Stannosis, Baritosis, Hard metal pneumoconiosis

What Are The Drivers Of The Pneumoconiosis Market?

The high prevalence rate of smoking is expected to propel the growth of the pneumoconiosis market going forward. Smoking is the act of inhaling and exhaling the smoke of burning tobacco, commonly through cigarettes, cigars, or pipes, and releases harmful chemicals into the body, affecting the lungs, heart, and overall health. The increasing prevalence rate of smoking is due to rising nicotine dependence and sustained tobacco use among specific age groups. The high prevalence rate of smoking enhances the pneumoconiosis by increasing the incidence of smoking-related lung diseases. For instance, in June 2023, according to The Guardian, a UK-based news organization, in 2022, 11.8% of 14- to 17-year-olds reported vaping, which increased to 14.5% in early 2023. Therefore, the high prevalence rate of smoking is driving the pneumoconiosis industry. Rising healthcare expenditures are expected to propel the growth of the pneumoconiosis market. Healthcare expenditures refer to the total amount of money spent on medical services, treatments, and healthcare-related products by individuals, governments, and organizations. Increasing healthcare expenditures are due to the rising prevalence of chronic diseases, which require long-term care and management. Healthcare expenditures support pneumoconiosis treatment by covering the costs of early diagnosis, continuous medical care, respiratory therapy, and access to specialized treatments and medications that help manage symptoms, slow disease progression, and enhance patients' quality of life. For instance, in May 2023, the Office for National Statistics, a UK-based statistics authority, reported that in 2023, healthcare expenditure in the UK was approximately $362.08 billion (£292 billion), reflecting a nominal increase of 5.6%. Further, healthcare spending as a share of gross domestic product (GDP) decreased slightly to 10.9% in 2023 from 11.1% in 2022. Therefore, rising healthcare expenditures will drive the growth of the pneumoconiosis industry.

Key Players In The Global Pneumoconiosis Market

Major companies operating in the pneumoconiosis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Eli Lilly and Co., Boehringer Ingelheim, Mylan Pharmaceuticals, Bristol Myers Squibb, Sino Biopharmaceutical Limited, Aurobindo Pharmaceuticals, Hikma Pharmaceuticals plc, Veracyte Inc., Lupin, GlaxoSmithKline plc, AstraZeneca plc, Novartis AG, Sanofi SA, Cipla Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Chiesi Farmaceutici S.p.A., Orion Corporation

Global Pneumoconiosis Market Trends and Insights

Major organizations are operating in the pneumoconiosis market, focusing on developing technological advancements such as AI-based portable diagnostic devices for early detection of silicosis and pneumoconiosis to enhance screening coverage, improve diagnostic accuracy, and reduce reliance on scarce radiology experts. An AI-based portable device uses deep learning algorithms to analyze chest X-rays and automatically highlight lung regions with potential pneumoconiosis-related abnormalities, allowing faster, more accurate detection and reducing human error. For instance, in November 2023, Malviya National Institute of Technology (MNIT), an India-based public technical university, launched the SILICO AI portable device for pneumoconiosis screening. The product allows rapid on-site analysis of chest X-rays in dust-exposed populations, improving early detection and enabling timely medical intervention compared to traditional manual X-ray reading, which is slower, resource-intensive, and subject to inter-reader variability.

Regional Outlook

North America was the largest region in the pneumoconiosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pneumoconiosis Market?

The pneumoconiosis market consists of sales of protective equipment, diagnostic imaging systems, and therapeutic drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pneumoconiosis Market Report 2026?

The pneumoconiosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pneumoconiosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.